Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for neuroprotection in Parkinson's disease
NCT01470027Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Jan 2012
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acetylcysteine in Parkinson's disease (PD) (3 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Cerebral Glutathione Levels at 4 weeks. Started Jan 2012; status: completed.
02
Drugs
acetylcysteine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01470027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01470027.